InMed Pharmaceuticals Inc. (INM)

InMed Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-8.16	-7.68	-7.95	-18.6	-10.2
Depreciation & Amortization	0.53	0.6	0.6	0.51	0.23
Loss (Gain) From Sale of Assets	-	-	-	0.01	0
Asset Writedown & Restructuring Costs	-	-	-	3.47	-
Stock-Based Compensation	0.12	0.14	0.28	0.78	0.61
Provision & Write-off of Bad Debts	0	-	0.05	-	-
Other Operating Activities	0.08	0.32	0.31	1.32	0.02
Change in Accounts Receivable	-0.11	-0.09	-0.22	-0.04	0.04
Change in Inventory	0.28	0.07	0.57	-2	-
Change in Accounts Payable	-0.25	0.05	-0.81	-0.81	0.35
Change in Other Net Operating Assets	-0.26	-0.39	-0.11	-0.22	-0.84
Operating Cash Flow	-7.77	-6.99	-7.28	-15.58	-9.79
Capital Expenditures	-	-0.01	-0.16	-0.04	-0
Cash Acquisitions	-	-	-0.5	-0.21	-
Investing Cash Flow	-	-0.01	-0.66	-0.67	-0
Short-Term Debt Repaid	-	-	-	-0.29	-
Total Debt Repaid	-	-	-	-0.29	-
Net Debt Issued (Repaid)	-	-	-	-0.29	-
Issuance of Common Stock	13.16	5.22	10.68	17.15	12.47
Other Financing Activities	-0.88	-0.56	-	-1.78	-1.62
Financing Cash Flow	12.27	4.65	10.68	15.07	10.85
Foreign Exchange Rate Adjustments	-	-	-	-	0.49
Net Cash Flow	4.5	-2.34	2.74	-1.19	1.56
Free Cash Flow	-7.77	-7	-7.45	-15.62	-9.79
Free Cash Flow Margin	-157.14%	-152.14%	-180.02%	-1434.03%	-
Free Cash Flow Per Share	-7.96	-18.36	-60.81	-557.14	-728.60
Cash Income Tax Paid	-	0.01	-	-	-
Levered Free Cash Flow	-4.22	-4.02	-4.81	-8.87	-5.35
Unlevered Free Cash Flow	-4.22	-4.02	-4.81	-8.87	-5.35
Change in Working Capital	-0.34	-0.37	-0.57	-3.07	-0.45

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q